GP2 and diabetes mellitus: In 2017, Cogger et al. identified GP2 as a specific marker of human pancreatic progenitors [10] Furthermore, on the basis of isolated GP2+ human pancreatic progenitors, Ameri et al. generated glucose-responsive beta cells that could be used in future diabetes cell therapies [11], making a case for the potential broad clinical application of GP2.